Tilray Inc (TLRY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tilray Inc stock (TLRY) is currently trading at $6.94. Tilray Inc PS ratio (Price-to-Sales) is 0.93. Analyst consensus price target for TLRY is $11.72. WallStSmart rates TLRY as Sell.
- TLRY PE ratio analysis and historical PE chart
- TLRY PS ratio (Price-to-Sales) history and trend
- TLRY intrinsic value — DCF, Graham Number, EPV models
- TLRY stock price prediction 2025 2026 2027 2028 2029 2030
- TLRY fair value vs current price
- TLRY insider transactions and insider buying
- Is TLRY undervalued or overvalued?
- Tilray Inc financial analysis — revenue, earnings, cash flow
- TLRY Piotroski F-Score and Altman Z-Score
- TLRY analyst price target and Smart Rating
Tilray Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Tilray Inc (TLRY) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Tilray Inc (TLRY) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Tilray Inc (TLRY) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Revenue growing slowly at 3.10% annually
Very low institutional interest at 10.49%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Tilray Inc (TLRY) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.93), Price/Book (0.46) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Growth concerns include Revenue Growth at 3.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -84.10%, Operating Margin at -9.14%, Profit Margin at -251.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -84.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TLRY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TLRY's Price-to-Sales ratio of 0.93x sits near its historical average of 0.98x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 15% below its historical high of 1.09x set in Mar 2026, and 8% above its historical low of 0.86x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.1x as trailing revenue scaled faster than the stock price.
Compare TLRY with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Tilray Inc (TLRY) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Tilray Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 837M with 310% growth year-over-year. The company is currently unprofitable, posting a -251.7% profit margin.
Key Findings
Revenue growing at 310% YoY, reaching 837M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
The company is unprofitable with a -251.7% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -25M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Tilray Inc maintain 310%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.09, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Tilray Inc.
Bottom Line
Tilray Inc is a high-conviction growth story with revenue accelerating at 310% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -251.7% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Tilray Inc(TLRY)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Tilray Inc. is dedicated to the research, cultivation, production and distribution of medicinal cannabis and cannabinoids. The company is headquartered in Leamington, Canada.